Patents by Inventor Timothy Paul Burkholder

Timothy Paul Burkholder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
    Patent number: 11649247
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: May 16, 2023
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Patric James Hahn, Zoran Rankovic
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
    Patent number: 11629156
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: April 18, 2023
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Raymond Gilmour, Patric James Hahn, Zoran Rankovic
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
    Publication number: 20210230185
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Application
    Filed: March 16, 2021
    Publication date: July 29, 2021
    Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
    Publication number: 20210206780
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
    Patent number: 11001596
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 11, 2021
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Patric James Hahn, Zoran Rankovic
  • Mutant IDH1 inhibitors
    Patent number: 10696665
    Abstract: The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 30, 2020
    Assignee: Eli Lilly and Company
    Inventors: Wenceslao Lumeras Amador, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, Raymond Gilmour, Patric James Hahn, Renato Alejandro Bauer, Zoran Rankovic
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
    Publication number: 20200079791
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Application
    Filed: December 8, 2017
    Publication date: March 12, 2020
    Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
  • MUTANT IDH1 INHIBITORS
    Publication number: 20190292175
    Abstract: The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 26, 2019
    Inventors: Wenceslao LUMERAS AMADOR, Serge Louis BOULET, Timothy Paul BURKHOLDER, Santiago CARBALLARES MARTIN, Raymond GILMOUR, Patric James HAHN, Renato Alejandro BAUER, Zoran RANKOVIC
  • 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
    Patent number: 10253041
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei Wu
  • 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS
    Publication number: 20180118759
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Application
    Filed: July 21, 2016
    Publication date: May 3, 2018
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei WU
  • NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS
    Publication number: 20160229835
    Abstract: The present invention provides novel pyridyloxyacetyl tetrahydroisoquinoline compounds that inhibit NAMPT and may be useful in the treatment of cancer.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 11, 2016
    Inventors: Timothy Paul Burkholder, Miriam Filadelfa Del Prado, Maria Carmen Fernandez, Lawrence Joseph Heinz, II, Lourdes Prieto, Genshi Zhao
  • Inhibitor of JAK1 and JAK2
    Patent number: 9062050
    Abstract: The present invention provides an amino pyrazole compound, which is 3-[(1R)-6-fluoro-2,3-dihydro-1H-inden-1-yl]-N-(3-methyl-IH-pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-5-amine, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 and JAK2 and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 23, 2015
    Assignee: ELI LILLY AND COMPANY
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton
  • INHIBITOR OF JAK1 AND JAK2
    Publication number: 20150133490
    Abstract: The present invention provides an amino pyrazole compound, which is 3-[(1R)-6-fluoro-2,3-dihydro-1H-inden-1-yl]-N-(3-methyl-1H-pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-5-amine, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 and JAK2 and, therefore may be useful in treating cancer.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 14, 2015
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton
  • AKT inhibitors
    Patent number: 8436002
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: May 7, 2013
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, Jr., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • AKT INHIBITORS
    Publication number: 20120149684
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Application
    Filed: October 20, 2010
    Publication date: June 14, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, JR., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110294792
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Purine derivatives as kinase inhibitors
    Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110207721
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Amino pyrazole compound
    Patent number: 7897600
    Abstract: The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton, Liandong Ma
  • AMINO PYRAZOLE COMPOUND
    Publication number: 20100286139
    Abstract: The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.
    Type: Application
    Filed: December 8, 2009
    Publication date: November 11, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Timothy Paul Burkholder, Liandong Ma, Joshua Ryan Clayton